Ginkgo Bioworks Holdings Inc - Company Profile
Powered by 
All the data and insights you need on Ginkgo Bioworks Holdings Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ginkgo Bioworks Holdings Inc Strategy Report
- Understand Ginkgo Bioworks Holdings Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ginkgo Bioworks Holdings Inc (Ginkgo Bioworks) is a biotechnology company that builds a leading platform for cell programming and biosecurity and provides automated organism engineering, enzyme discovery, fermentation and cultured fragrance solutions through its subsidiary. The company is into genetic engineering to produce bacteria with industrial applications. Its cell programming platform is used to program cells to enable the biological production of products, such as food ingredients, novel therapeutics and chemicals. Ginkgo Bioworks offerings include vaccines, enzymes, proteins, small molecules, strain optimization, fermentation and scale-up and biosecurity. The company serves industries including agriculture, specialty chemicals, food, consumer products and pharmaceuticals. Ginkgo Bioworks is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
8th Floor, 27 Drydock Avenue, Boston, Massachusetts, 02210
Website
www.ginkgobioworks.com
Telephone
1 877 4225362
No of Employees
1,292
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DNA (NYSE)
Revenue (2022)
$251.5M
-47.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
57.6%
(2022 vs 2021)
Market Cap*
$1.6B
Net Profit Margin (2022)
XYZ
19.4%
(2022 vs 2021)
* As of and is in US$
Ginkgo Bioworks Holdings Inc premium industry data and analytics
Products and Services
| Services |
|---|
| Cell Programming Services |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Asset Purchase | In April, the company acquired Modulus Therapeutics' cell therapy platform assets. |
| 2024 | Contracts/Agreements | In April, the company entered into a partnership with Imagindairy to combine its protein expression services with Imagindairy’s process development to produce animal-free dairy proteins. |
| 2024 | Contracts/Agreements | In April, the company secured a contract from the Bill & Melinda Gates Foundation to develop an open-access, AI-powered measles forecasting model, aimed at enabling proactive public health interventions. |
Competitor Comparison
| Key Parameters | Ginkgo Bioworks Holdings Inc | Cromsource Inc | H&J CRO International Inc | Kindred Healthcare LLC | Medpace Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Cary | Union | Louisville | Cincinnati |
| State/Province | Massachusetts | North Carolina | New Jersey | Kentucky | Ohio |
| No. of Employees | 1,292 | - | - | 33,000 | 5,600 |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marijn E. Dekkers | Chairman | Executive Board | - | 66 |
| Jason Kelly | Director; Chief Executive Officer | Executive Board | 2008 | 43 |
| Reshma Shetty | Director; President; Chief Operating Officer | Executive Board | 2008 | 43 |
| Mark Dmytruk | Chief Financial Officer | Senior Management | 2020 | 52 |
| Steven P. Coen | Chief Accounting Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer